Holds one active US DMF and 2 valid CEPs for xylometazoline, filing since 1991. Its 2023 FDA inspection closed as VAI.
Holds one active US DMF and 2 valid CEPs for xylometazoline, filing since 1991. Its 2023 FDA inspection closed as VAI.
Holds one active US DMF and one valid CEP for xylometazoline, filing since 2024. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one valid CEP for xylometazoline, filing since 2020. Its 2024 FDA inspection closed as VAI.
Holds one valid CEP for xylometazoline, filing since 2022. Its 2025 FDA inspection closed as VAI.
Registered with DAV (Vietnam) for xylometazoline. Its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for xylometazoline. Its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for xylometazoline. Its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for xylometazoline. Its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for xylometazoline. Its GMP is recognised in 1 market.
Registered with DAV (Vietnam) for xylometazoline. Its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for freeFixed-dose combinations containing xylometazoline. Each page leads with the verified API makers of every component.